Journal of Pharmacy and Pharmaceutical Sciences最新文献

{"title":"Ketamine enhancement of dexmedetomidine attenuation of methamphetamine-induced agitation in rats.","authors":"Madhuri Budamkayala, Jyostna Yalakala, Madison B Skeen, Surya Karuturi, Chelsey McPhillen, Kristen Bailey, Todd H Davies, Michael D Hambuchen","doi":"10.3389/jpps.2026.16294","DOIUrl":"https://doi.org/10.3389/jpps.2026.16294","url":null,"abstract":"<p><p>Methamphetamine (METH)-induced agitation, a major concern in acute METH intoxication, is currently treated with benzodiazepines. Due to current polysubstance use patterns in METH consumption, this treatment may fatally exacerbate respiratory depression produced by opioid adulterants or intentionally co-administered opioids. We previously showed that the α2-agonist dexmedetomidine (DEX), which does not potentiate opioid-induced respiratory depression in clinical practice, can be safely and effectively co-administered with naloxone to attenuate METH-induced agitation following naloxone reversal in METH-fentanyl co-intoxicated rats. While the unique arousability of DEX-induced sedation is clinically useful, the current study tested the safety and efficacy of DEX and adjunctive ketamine (KET) in producing deeper, less arousable sedation when needed (i.e., for severe agitation or to facilitate an intricate procedure). Fifteen minutes after 1 mg/kg METH administration in male rats (simulating treatment of naloxone-unmasked agitation with a delay), low-dose (0.032 mg/kg) DEX ± (56 mg/kg) KET, high-dose (0.18 mg/kg) DEX, or saline was administered. Key measurements included METH-induced locomotor activity (a rat model of agitation), the rat coma scale (a quantification of arousability), and α₂-agonist class side effects. Both high-dose DEX and DEX-KET almost completely attenuated METH-induced locomotor activity for 90 min after administration, but with the combination the sedation was deeper during the most intense METH-induced stimulation, and the α₂-agonist side effects were less intense and of shorter duration. These data provide proof-of-concept support for the potential use of DEX-KET in producing deeper sedation in METH-induced agitation.</p>","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"29 ","pages":"16294"},"PeriodicalIF":4.3,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13124640/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147823090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of hematocrit-adjusted conversion strategies for mycophenolic acid and tacrolimus monitoring using volumetric absorptive microsampling in lung and renal transplant recipients.","authors":"Liang Juan, Chih-Ning Cheng, Wen-Chi Chang, Huai-Hsuan Chiu, Chao-Wen Lu, Hsao-Hsun Hsu, Ching-Hua Kuo, Yu-Ju Tseng","doi":"10.3389/jpps.2026.16123","DOIUrl":"https://doi.org/10.3389/jpps.2026.16123","url":null,"abstract":"<p><strong>Objectives: </strong>Mycophenolic acid (MPA) and tacrolimus (TAC) exhibit substantial pharmacokinetic variability, and volumetric absorptive microsampling (VAMS) offers a minimally invasive alternative for therapeutic drug monitoring (TDM). This study aimed to develop a VAMS-based method for MPA and TAC quantifications and systematically evaluate hematocrit (Hct)-adjusted conversion strategies.</p><p><strong>Methods: </strong>Adult transplant recipients receiving mycophenolate mofetil or mycophenolate sodium were prospectively enrolled. Paired plasma (MPA), whole-blood (TAC), and VAMS samples were analyzed using validated LC-MS/MS method for simultaneous MPA and TAC quantification. Multiple Hct-adjusted conversion approaches for MPA were compared using Passing-Bablok regression, Bland-Altman analysis, and predictive performance metrics. Clinical applicability was assessed through scenario-based AUC estimation MPA AUC estimations under different sampling schemes.</p><p><strong>Results: </strong>LC-MS/MS method for quantifying MPA and TAC in VAMS exhibited good linearity (R² > 0.99) and accuracy within 85-115% across validation ranges (10-20,000 ng/mL for MPA; 0.5-500 ng/mL for TAC). Formula A-ind [(VAMS/1 - individual Hct) x f_bpp], where f_bpp represents the MPA protein binding fraction (0.97), achieved clinical agreement in 86% of samples for the conversion of MPA concentrations between VAMS and plasma, representing the most balanced between predictive reliability and operational feasibility. TAC concentrations from VAMS correlated strongly with whole blood values without requiring Hct correction. Clinical case applications showed that rich eight-point VAMS sampling enabled more accurate AUC estimations than conventional three-point schemes, further highlighting the advantages of using VAMS for MPA TDM.</p><p><strong>Conclusion: </strong>This validated VAMS-based approach offers a minimally invasive and clinically applicable alternative to venous sampling for MPA and TAC monitoring. Incorporating individualized Hct adjustments improves predictive performance, supporting conditional integration of VAMS into routine TDM.</p>","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"29 ","pages":"16123"},"PeriodicalIF":4.3,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13061867/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147678034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrative deep learning strategies to enhance early-stage drug discovery: optimizing computational structure-activity modeling for pharmacotherapeutic innovation.","authors":"Sarah Rezazi, Cherif Si-Moussa, Salah Hanini","doi":"10.3389/jpps.2026.16155","DOIUrl":"10.3389/jpps.2026.16155","url":null,"abstract":"<p><p>The integration of computational intelligence into therapeutic development is increasingly important for accelerating early-stage drug discovery and improving compound prioritization. In this study, we developed an optimized neural network-based predictive framework to support the identification of bioactive compounds with analgesic potential. A dataset of 532 structurally diverse molecules described by 227 molecular descriptors was analyzed, and a stepwise feature elimination procedure reduced the descriptor set to 105 informative variables, improving model robustness and reducing redundancy. The optimized artificial neural network, trained using the Levenberg-Marquardt algorithm, achieved a correlation coefficient of 95.9% with a prediction error of 0.433%, outperforming conventional statistical approaches reported for comparable QSAR tasks. Additional analysis links key descriptor groups, including connectivity and polarity parameters, to physicochemical properties relevant to analgesic activity, improving interpretability for medicinal chemistry applications. The framework is intended to support computational screening and candidate prioritization prior to experimental validation, thereby contributing to more efficient pharmacotherapeutic discovery workflows. This work highlights how data-driven modeling can complement translational strategies aimed at accelerating drug discovery pipelines.</p>","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"29 ","pages":"16155"},"PeriodicalIF":4.3,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13014046/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147522342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Career commitment and professional satisfaction among Romanian pharmacy graduates: a nationwide cross-sectional survey.","authors":"Marius Călin Cherecheş, Aura Rusu","doi":"10.3389/jpps.2026.15679","DOIUrl":"https://doi.org/10.3389/jpps.2026.15679","url":null,"abstract":"<p><strong>Introduction: </strong>Professional satisfaction is a key determinant of career commitment and workforce sustainability and retention in the pharmacy sector. The study examines professional satisfaction among Romanian pharmacy graduates by analysing hygiene factors, intrinsic motivators, and perceptions of pay equity, assessing sector-based differences and exploring associations between these dimensions and long-term career commitment.</p><p><strong>Methods: </strong>A cross-sectional survey was conducted among 473 pharmacy graduates (2009-2023). Professional satisfaction was evaluated using 13 structured items from a questionnaire that covered hygiene factors, intrinsic motivators, and perceptions of pay equity. Reliability was assessed with Cronbach's α. Descriptive statistics, ANOVA, and chi-square tests were applied.</p><p><strong>Results: </strong>The Hygiene Index (α = 0.67; M = 3.28, SD = 0.76) and Motivators Index (α = 0.80; M = 3.22, SD = 0.86) reflected moderate satisfaction. The Pay-Equity Index showed very low scores (α = 0.77; M = 1.86, SD = 0.70). Salary satisfaction (M = 2.22, SD = 1.23) and expectations for future salary increases (M = 2.21, SD = 1.06) were rated as the lowest. Over 80% perceived their income as \"much lower\" than that of physicians or dentists. Only 7% stated they would \"definitely\" choose pharmacy again, while 46% responded \"definitely not,\" and over 70% expressed some degree of non-recommitment. Community pharmacists consistently reported lower satisfaction across indices compared to peers in industry or education.</p><p><strong>Conclusion: </strong>Romanian pharmacists report moderate satisfaction with work conditions and collegiality, but widespread dissatisfaction with pay equity and career opportunities. Alarmingly, almost three-quarters of pharmacists said they would not choose pharmacy again, indicating a lack of professional commitment. The results raise substantial concerns about professional commitment and suggest a risk to the long-term sustainability of the Romanian pharmacy workforce. Urgent policy interventions are needed to address salary disparities, improve recognition, and expand career development pathways to retain qualified professionals and ensure the resilience of pharmaceutical services.</p>","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"29 ","pages":"15679"},"PeriodicalIF":4.3,"publicationDate":"2026-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12999541/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147500364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rethinking asthma therapy, part 1: transdermal delivery of β₂-agonists.","authors":"Joseph Correa, Nicole K Brogden","doi":"10.3389/jpps.2026.15713","DOIUrl":"https://doi.org/10.3389/jpps.2026.15713","url":null,"abstract":"<p><p>Asthma and allergies are closely related conditions affecting millions of people around the world. Current treatment options cover many classes of drugs for both acute and ongoing conditions. β2-agonists, leukotriene modifiers, and corticosteroids represent some of the common types of drugs utilized in asthma management. These medications are often delivered via inhalation, oral, or parenteral methods, but each of these modalities faces challenges due to improper technique with inhalers, lessened oral bioavailability due to first-pass metabolism, and reduced compliance of injectable medicines. Transdermal drug delivery may offer a beneficial route of administration that overcomes these barriers as a painless, self-administered form that bypasses first-pass metabolism and can reduce dosing frequency with longer drug release profiles and reduced fluctuations in plasma drug levels. In this two-part mini-review series we will summarize the current literature on transdermal systems for asthma and allergy therapy. Here in Part 1, we cover β2-agonists and discuss the potential of transdermal systems for these drugs. While the body of work with transdermal β2-agonists for asthma treatment is limited, there is still evidence that transdermal systems for asthma has potential to greatly shift the field of asthma therapeutics.</p>","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"29 ","pages":"15713"},"PeriodicalIF":4.3,"publicationDate":"2026-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12995819/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147488277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rethinking asthma therapy, part 2: transdermal strategies for adjunct asthma and allergy treatments.","authors":"Joseph Correa, Nicole K Brogden","doi":"10.3389/jpps.2026.15714","DOIUrl":"https://doi.org/10.3389/jpps.2026.15714","url":null,"abstract":"<p><p>Asthma and allergies affect millions of people globally. Avoiding triggers and allergens is a basic management technique for all asthma subtypes (>80% of asthma patients also suffer from allergies), and pharmacological treatment is the cornerstone for acute exacerbations and ongoing maintenance. Typical treatment options for asthma include inhaled, oral, or injectable dosage forms. However, transdermal drug delivery has great potential to provide an alternative route of administration of necessary asthma and allergy therapies that have traditionally been given in other dosage forms. In Part 1 of this two-part series, we discussed the work done towards incorporating short- and long-acting β2-agonists into transdermal drug delivery systems. Here in part 2, we describe the current literature for transdermal applications of leukotriene antagonists, theophylline, and other adjunct medications that do not fall into one specific drug class. A brief overview of biologics, particularly monoclonal antibodies, and the role in asthma is also included, including some context of transdermal mAb delivery for disease states beyond asthma. Because of the relatedness of asthma and allergies, transdermal applications for allergen immunotherapy is also discussed.</p>","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"29 ","pages":"15714"},"PeriodicalIF":4.3,"publicationDate":"2026-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12995823/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147488222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Volume 2: real world evidence (RWE): paths to enhancing patient access to new medications.","authors":"Allison Wills, Catherine Y Lau","doi":"10.3389/jpps.2026.16236","DOIUrl":"https://doi.org/10.3389/jpps.2026.16236","url":null,"abstract":"","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"29 ","pages":"16236"},"PeriodicalIF":4.3,"publicationDate":"2026-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12995811/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147488244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum: Optimized <i>Ginkgo biloba</i> extract EGb 761^®: boosted therapeutic benefits with minimized CYP enzyme interference.","authors":"Sunbeom Kwon, Suji Jeong, Seulah Lee","doi":"10.3389/jpps.2026.15563","DOIUrl":"https://doi.org/10.3389/jpps.2026.15563","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/jpps.2025.14614.].</p>","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"29 ","pages":"15563"},"PeriodicalIF":4.3,"publicationDate":"2026-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12954404/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147357025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of cryoprotectant and storage conditions on the aggregation of poly(ethylene glycol)-poly(α-benzyl carboxylate-ε-caprolactone) nanoparticles.","authors":"Nasim Sarrami, Soheyla Honary, Mohammad Reza Vakili, Afsaneh Lavasanifar","doi":"10.3389/jpps.2026.15721","DOIUrl":"10.3389/jpps.2026.15721","url":null,"abstract":"<p><strong>Introduction: </strong>The preparation of nanoparticles (NPs) in aqueous media leads to thermodynamic instability and aggregation during storage. The objective of this study was to identify an optimum condition for the storage of poly(ethylene glycol)-poly(α-benzyl carboxylate-ε-caprolactone) (PEG-PBCL) NPs with minimum to no NP aggregation.</p><p><strong>Methods: </strong>Nanoparticles were prepared from PEG-PBCL of varied PBCL degrees of polymerization. Prepared NPs were either subjected to freeze-thaw or lyophilization with the addition of sugars or polyethylene glycols (PEGs) of varying molecular weight. The average diameter and polydispersity of NPs before and after freeze-thaw or lyophilization/reconstitution in water was assessed by dynamic light scattering and transmission electron microscopy (TEM). Differential Scanning Calorimetry (DSC) was used to compare the thermal behaviour of NPs before and after selected storage conditions.</p><p><strong>Results: </strong>Irrespective of the DP of PBCL, minimum size growth in the freeze-drying method was achieved when PEG3350 and methoxy-PEG 5000 were used as cryoprotectant at a w/w ratio of 4:1 to PEG-PBCL. Under this condition, NP size increased about 2-fold after reconstitution. In the freeze-thaw method, both sucrose and PEGs of different molecular weights, protected the PEG-PBCL NPs of different PBCL length from significant size growth where average particle size growth was not more than 1.20 folds.</p><p><strong>Conclusion: </strong>Our findings suggest that freeze-thawing of PEG-PBCL NP using sucrose or PEG can prevent the NP aggregation and is the best method for PEG-PBCL NP storage.</p>","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"29 ","pages":"15721"},"PeriodicalIF":4.3,"publicationDate":"2026-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12945844/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147327322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted therapy and biomarker-guided applications of ecofriendly silver nanoparticles in precision oncology.","authors":"Haider Hamzah","doi":"10.3389/jpps.2025.15403","DOIUrl":"https://doi.org/10.3389/jpps.2025.15403","url":null,"abstract":"<p><p>Eco-friendly silver nanoparticles (eco-AgNPs) represent a promising convergence of green nanotechnology and precision medicine for cancer treatment. This minireview examines the therapeutic potential of silver nanoparticles (AgNPs) synthesized through eco-friendly methods using plant extracts and microorganisms. These eco-friendly AgNPs demonstrate enhanced biocompatibility and selective cytotoxicity against malignant cells. These nanoparticles target cancer through multiple mechanisms including reactive oxygen species generation, apoptosis induction, and cell cycle disruption. Selectivity is achieved through surface functionalization with targeting moieties such as antibodies and aptamers that recognize overexpressed tumor receptors. The integration of biomarker-guided design enables tumor-specific delivery by exploiting unique metabolic signatures and cellular markers characteristic of different cancer types. Furthermore, AgNP-based theranostic platforms offer simultaneous diagnostic imaging and therapeutic intervention, providing real-time assessment of treatment response and enabling personalized dosing strategies. However, clinical translation faces significant challenges including potential long-term toxicity, standardization of synthesis protocols, and regulatory approval pathways. Successful clinical implementation will require interdisciplinary collaboration to optimize nanoparticle design, establish safety profiles, and develop combination therapies that maximize therapeutic benefits while minimizing side effects. Eco-AgNPs thus offer a transformative approach to cancer treatment that combines environmental sustainability with precision targeting capabilities.</p>","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"28 ","pages":"15403"},"PeriodicalIF":4.3,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12834829/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146094594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}